FRLN
NASDAQFreeline Therapeutics Holdings plc
Latest news
25 items- PRFreeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingLate-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease Poster presentation to highlight Freeline's GBA1 Parkinson's disease research program LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics today announced the acceptance of multiple abstracts, including one for a late-breaking oral presentation on new clinical data from its Gaucher disease program, at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland. "Gaucher disease is a severe and progressive disorder that leads to a wide range of symptoms, including enlarged organs, bone pain and fractures, low bl
- SECSEC Form 15-12G filed by Freeline Therapeutics Holdings plc15-12G - Freeline Therapeutics Holdings plc (0001810031) (Filer)
- SECSEC Form EFFECT filed by Freeline Therapeutics Holdings plcEFFECT - Freeline Therapeutics Holdings plc (0001810031) (Filer)
- SECSEC Form S-8 POS filed by Freeline Therapeutics Holdings plcS-8 POS - Freeline Therapeutics Holdings plc (0001810031) (Filer)
- SECSEC Form S-8 POS filed by Freeline Therapeutics Holdings plcS-8 POS - Freeline Therapeutics Holdings plc (0001810031) (Filer)
- SECSEC Form S-8 POS filed by Freeline Therapeutics Holdings plcS-8 POS - Freeline Therapeutics Holdings plc (0001810031) (Filer)
- SECSEC Form S-8 POS filed by Freeline Therapeutics Holdings plcS-8 POS - Freeline Therapeutics Holdings plc (0001810031) (Filer)
- SECSEC Form POS AM filed by Freeline Therapeutics Holdings plcPOS AM - Freeline Therapeutics Holdings plc (0001810031) (Filer)
- 13D/GSEC Form SC 13D/A filed by Freeline Therapeutics Holdings plc (Amendment)SC 13D/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
- SECSEC Form SC 13E3/A filed by Freeline Therapeutics Holdings plc (Amendment)SC 13E3/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
- SECSEC Form 25-NSE filed by Freeline Therapeutics Holdings plc25-NSE - Freeline Therapeutics Holdings plc (0001810031) (Subject)
- SECSEC Form 6-K filed by Freeline Therapeutics Holdings plc6-K - Freeline Therapeutics Holdings plc (0001810031) (Filer)
- PRAcquisition of Freeline by Syncona Becomes EffectiveLONDON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) ("Freeline") and Syncona Ltd ("Syncona") today announced that, in connection with Syncona's acquisition of Freeline by way of a scheme of arrangement (the "Scheme"), the Scheme has been sanctioned by the Court and the court order (together with a copy of the scheme circular published by Freeline on January 18, 2024 (the "Scheme Circular") has been delivered to the Registrar of Companies. Accordingly, the Scheme has become Effective in accordance with its terms and the entire issued share capital of Freeline is now owned or controlled by Syncona Portfolio Limited. Capitalized terms in this an
- 13D/GSEC Form SC 13G/A filed by Freeline Therapeutics Holdings plc (Amendment)SC 13G/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
- 13D/GSEC Form SC 13G/A filed by Freeline Therapeutics Holdings plc (Amendment)SC 13G/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
- SECSEC Form 6-K filed by Freeline Therapeutics Holdings plc6-K - Freeline Therapeutics Holdings plc (0001810031) (Filer)
- PRFreeline Shareholders Approve Acquisition by SynconaLONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) ("Freeline") and Syncona Ltd ("Syncona") today announced that Freeline's shareholders have approved the proposal for Bidco 1354 Limited ("Bidco"), a wholly owned subsidiary of Syncona Portfolio Limited ("Syncona Portfolio"), to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share ("ADS") in cash (the "Acquisition"). As previously announced, Freeline and Bidco entered into an implementation agreement on November 22, 2023 to implement the Acquisition by means of a scheme of arrangement pursuant to Part 26 of the UK Companies Act 2006 (the "Sche
- 13D/GSEC Form SC 13G/A filed by Freeline Therapeutics Holdings plc (Amendment)SC 13G/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
- SECSEC Form 6-K filed by Freeline Therapeutics Holdings plc6-K - Freeline Therapeutics Holdings plc (0001810031) (Filer)
- SECSEC Form SC 13E3/A filed by Freeline Therapeutics Holdings plc (Amendment)SC 13E3/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
- SECSEC Form SC 13E3 filed by Freeline Therapeutics Holdings plcSC 13E3 - Freeline Therapeutics Holdings plc (0001810031) (Subject)
- SECSEC Form 6-K filed by Freeline Therapeutics Holdings plc6-K - Freeline Therapeutics Holdings plc (0001810031) (Filer)
- NEWSHC Wainwright & Co. Downgrades Freeline Therapeutics to Neutral, Lowers Price Target to $6.5HC Wainwright & Co. analyst Patrick Trucchio downgrades Freeline Therapeutics (NASDAQ:FRLN) from Buy to Neutral and lowers the price target from $15 to $6.5.
- 13D/GSEC Form SC 13D/A filed by Freeline Therapeutics Holdings plc (Amendment)SC 13D/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
- NEWSFreeline Therapeutics shares are trading higher after the company announced it entered into a definitive agreement to be acquired by Syncona.
FRLN FAQ
7 questionsWhat does Freeline Therapeutics Holdings plc do?
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to...Where does FRLN stock trade?
Freeline Therapeutics Holdings plc (FRLN) is listed on NASDAQ.What sector and industry is FRLN in?
Freeline Therapeutics Holdings plc operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Freeline Therapeutics Holdings plc go public?
Freeline Therapeutics Holdings plc (FRLN) completed its IPO in 2020.What are analysts saying about FRLN?
Freeline Therapeutics Holdings plc has had 6 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight on 2022-02-01. Recent price targets range from $800.00 to $2000.00.What companies are similar to FRLN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare FRLN side-by-side with any of them on Quantisnow.How can I track FRLN on Quantisnow?
Quantisnow aggregates Freeline Therapeutics Holdings plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FRLN to receive live email and push alerts on every new disclosure.